Multiple Myeloma Market Insight, Epidemiology and Forecast Report 2021-2030 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Multiple Myeloma- Market Insight, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
This 'Multiple Myeloma (MM)-Market Insights, Epidemiology and Market Forecast - 2030' report delivers an in-depth understanding of the MM, historical and forecasted epidemiology as well as the MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), Japan and China.
The MM market report provides current treatment practices, emerging drugs, MM market share of the individual therapies, current and forecasted MM market size from 2017 to 2030 segmented by eight major markets. The Report also covers current MM treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.
Multiple Myeloma Treatment
The main treatment options include stem cell transplant, chemotherapy, targeted therapy, corticosteroids, proteasome inhibitors, immunomodulators, monoclonal antibodies, surgery, and radiation therapy. Also, the survival of patients with myeloma has improved due to the development and approval of new treatments. MM treatment strategies have also evolved with the emergence of new therapies with a novel mechanism of action and also with more complex combination regimens being used, such as quadruplets, triplets, and doublets.
Multiple Myeloma (MM) Epidemiology
The Multiple Myeloma epidemiology division provide the insights about historical and current Multiple Myeloma patient pool and forecasted trend for each eight major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The MM epidemiology division provides insights about historical and current patient pool and forecasted trends for each eight major countries. The Multiple Myeloma epidemiology data are studied through Multiple Myeloma possible division to give a better understanding of the Disease scenario in the 8MM.
The disease epidemiology covered in the report provides historical as well as forecasted Multiple Myeloma epidemiology [segmented as Total Incidence of Multiple Myeloma, Total Symptomatic Cases of Multiple Myeloma, Total Incident Cases of Multiple Myeloma Segmented by Gender, Total Diagnosed cases of Multiple Myeloma by Age Distribution, Total Cases of Multiple Myeloma by Line of Treatment] scenario of Multiple Myeloma in the 8MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China from 2017 to 2030
Multiple Myeloma Drug Chapters
Drug chapter segment of the Multiple Myeloma report encloses the detailed analysis of Multiple Myeloma marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Multiple Myeloma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Multiple Myeloma Market Outlook
According to the publisher, the Multiple Myeloma market size in the 8MM is expected to change at a CAGR of 4.3% during the study period (2017-2030). In the total market size of Multiple Myeloma in the 8MM, the United States accounted for the highest market size in 2020 followed by Japan, Germany, and France.
Multiple Myeloma Pipeline Development Activities
- Venetoclax (ABT-199): AbbVie and Roche
- JNJ-68284528 (LCAR-B38M/JNJ-4528): Janssen Biotech/Nanjing Legend Biotech
- Keytruda (Pembrolizumab): Merck Sharp & Dohme Corp.
- Cetrelimab (JNJ-63723283): Janssen Research & Development
- REGN5458: Regeneron Pharmaceuticals
- Felzartamab (MOR202): MorphoSys AG/I-Mab Biopharma
- Chidamide (Epidaza): Chipscreen Biosciences
- Iberdomide (CC-220): Bristol-Myers Squibb/Celgene
- Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy: RAPA Therapeutics
- Encorafenib in combination with Binimetinib: Pfizer (Array Biopharma)
- CLR 131 (131-CLR1404): Cellectar Biosciences
- BL-8040: BioLineRx
- GVAX (GM-CSF) Vaccine: Celgene/Aduro Biotech
- ECT-001: ExCellThera
- TAK-079: Takeda
- GBR 1342 (ISB 1342): Glenmark (Ichnos Sciences SA)
- P-BCMA-101 CAR-T cells: Poseida Therapeutics
- Opdivo (Nivolumab): Bristol-Myers Squibb
- PBCAR269A: Precision BioSciences
- MP0250: Molecular Partners AG
- Teclistamab (JNJ-7957; JNJ-64007957): Janssen Pharmaceutical
- Descartes-11: Cartesian Therapeutics
- Imfinzi (Durvalumab): AstraZeneca
- Imbruvica (Ibrutinib): Abbvie (Pharmacyclics) and Johnson & Johnson
Pipeline Development Activities
- In June 2021, the Janssen Pharmaceutical Companies of Johnson & Johnson announced that the USFDA has granted Breakthrough Therapy Designation for teclistamab in the treatment of relapsed or refractory multiple myeloma. This distinction for teclistamab, an off-the-shelf, T-cell redirecting, a bispecific antibody targeting both BCMA and CD3 receptors, follows a PRIME designation from the EMA received earlier this year.
- In May 2021, Oncopeptides has announced positive results from the OCEAN study, which compared the effectiveness and safety of melflufen with pomalidomide in patients with relapsed refractory multiple myeloma. The phase III OCEAN study is a global, randomized, head-to-head, open-label study, evaluating the efficacy and safety of melflufen and dexamethasone, versus pomalidomide and dexamethasone in patients with relapsed refractory multiple myeloma who have received 2-4 prior therapies.
- In May 2021, the USFDA granted priority review to the Biologics License Applications (BLA) for ciltacabtagene autoleucel for the treatment of patients with relapsed/refractory multiple myeloma. The regulatory agency is expected to decide on the application by November 29, 2021, under the Prescription Drug User Fee Act.
- In April 2021, Legend Biotech announced the submission of a MAA to the EMA seeking approval of ciltacabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma. The EMA's Committee for Medicinal Products for Human Use (CHMP) granted accelerated assessment for this MAA.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/13y3w2
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900